Looking for biomarkers in metronomic chemotherapy

Metronomics and low/middle income countries, especially in breast cancer

Continual low-dose metronomic chemotherapy as potentially preferable to aggressive strategies

Quality of life and cost advantages of metronomics and drug repurposing

Drug repurposing as an alternative to costly drugs such as herceptin in breast cancer

Benefits of metronomic chemotherapy and the aims of the Metronomic Global Health Initiative

Cost-effectiveness of metronomic approach to neuroblastoma and its use in combination with other therapies

New metronomic approach to neuroblastoma

Betablockers repurposed to treat neuroblastoma

Diabetes drug, metformin, repurposed for use against several cancers including breast

Advances in multiple myeloma: Expert panel discussion

Industry view of targeted therapy combinations in oncology